[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585606":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":7,"enrollmentInfo":32,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":7,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":7},{"fullName":5,"class":6},"Shanghai Chest Hospital","OTHER",null,[9,11],{"type":6,"name":10,"description":10,"armGroupLabels":7,"otherNames":7},"No intervention administered",{"type":6,"name":12,"description":12,"armGroupLabels":7,"otherNames":7},"Non Interventional Study",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Li Zi ming","CONTACT","18017321562","liziming1980@163.com",{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ziming Li","Chief Physician","100585606","resistance-mechanisms-and-sequential-treatment-strategies-following-first-line-lorlatinib-in-alk-positive-nsclc-100585606",false,"NCT06904547","Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC","Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC: A Multi-center, Observational, Prospective Real-world Cohort Study (LORES)","Inclusion Criteria\n\n1. Age: Patients aged 18 years or older;\n2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC\n3. Documened ALK resrrangemen by approved test (eg.. FisH,IHC. .r NGS).\n4. first-line loelaninab treatment fom Apr2023-Apr-2027.\n5. Evidenoe of popression to first-line lorlztinib within 2 weekes.\n\nExclusion Criteria\n\n1. Previous treatment with other ALK-TKIs: Patients who have previously received any ALK TKI other than lorlatinib;\n2. Concomitant medications: Patients who have received any systemic anti-tumor treatment other than lorlatinib before enrollment.","ALL","18 Years",{"count":33,"type":34},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, non-interventional, single-arm, real-world study planned to be conducted in China, aimed at exploring the resistance mechanisms of first-line lorlatinib treatment in patients with ALK-positive locally advanced or metastatic NSCLC, as well as the efficacy and safety of sequential treatments following lorlatinib resistance in the real-world setting.",[38],"ALK-Positive NSCLC","NOT_YET_RECRUITING","2025-04-08",{"date":42,"type":43},"2025-04-11","ACTUAL",{"date":45,"type":34},"2025-04-20",{"date":47,"type":34},"2030-12-31",{"name":5,"class":6}]